tbuckley/cabot-search huggingface dataset:
Genome-wide analysis of differential transcriptional and epigenetic variability across human immune cell types
Authors: Simone Ecker, Lu Chen, Vera Pancaldi, Frederik O. Bagger, José María Fernández, Enrique Carrillo de Santa Pau, David Juan, Alice L. Mann, Stephen Watt, Francesco Paolo Casale, Nikos Sidiropoulos, Nicolas Rapin, Angelika Merkel, Hendrik G. Stunnenberg, Oliver Stegle, Mattia Frontini, Kate Downes, Tomi Pastinen, Taco W. Kuijpers, Daniel Rico, Alfonso Valencia, Stephan Beck, Nicole Soranzo, Dirk S. Paul
Journal: Genome biology (2017)

A healthy immune system requires immune cells that adapt rapidly to environmental challenges. This phenotypic plasticity can be mediated by transcriptional and epigenetic variability.We apply a novel analytical approach to measure and compare transcriptional and epigenetic variability genome-wide across CD14+CD16- monocytes, CD66b+CD16+ neutrophils, and CD4+CD45RA+ naïve T cells from the same 125 healthy individuals. We discover substantially increased variability in neutrophils compared to monocytes and T cells. In neutrophils, genes with hypervariable expression are found to be implicated in key immune pathways and are associated with cellular properties and environmental exposure. We also observe increased sex-specific gene expression differences in neutrophils. Neutrophil-specific DNA methylation hypervariable sites are enriched at dynamic chromatin regions and active enhancers.Our data highlight the importance of transcriptional and epigenetic variability for the key role of neutrophils as the first responders to inflammatory stimuli. We provide a resource to enable further functional studies into the plasticity of immune cells, which can be accessed from: http://blueprint-dev.bioinfo.cnio.es/WP10/hypervariability .
GVHD Prophylaxis with Cyclosporine + Mycophenolate Mofetil Improves Outcome Compared to Cyclosporine Alone in Patients Receiving Reduced Intensity Conditioning Hematopoietic Stem-Cell Transplantation from Unrelated Donor for Hematological Diseases.
Authors: Eolia Brissot-Davaine, Philippe Moreau, Sameh Ayari, Jacques Delaunay, Thierry Guillaume, Jean-Baptiste Pelletier, Jean-Luc Harousseau, Patrice Chevallier
Journal: Blood (2007)
Chemotherapy Use and Survival Among Young and Middle-Aged Patients With Colon Cancer
Authors: Janna Manjelievskaia, Derek Brown, Katherine A. McGlynn, William Anderson, Craig D. Shriver, Kangmin Zhu
Journal: JAMA Surgery (2017)

Treatment options for patients with young-onset colon cancer remain to be defined and their effects on prognosis are unclear.To investigate receipt of adjuvant chemotherapy by age category (18-49, 50-64, and 65-75 years) and assess whether age differences in chemotherapy matched survival gains among patients diagnosed as having colon cancer in an equal-access health care system.This cohort study was based on linked and consolidated data from the US Department of Defense's Central Cancer Registry and Military Heath System medical claims databases. There were 3143 patients aged 18 to 75 years with histologically confirmed primary colon adenocarcinoma diagnosed between 1998 and 2007. This study was conducted from December 2015 to August 2016.Patients who underwent surgery and postoperative systemic chemotherapy.The primary outcome measure of the study was overall survival of patients who only received surgery and those who received both surgery and postoperative systemic chemotherapy.Of the 3143 patients, 1841 were men (58.6%). Young (18-49 years) and middle-aged (50-64 years) patients were 2 to 8 times more likely to receive postoperative systemic chemotherapy compared with older patients (65-75 years) across all tumor stages. Middle-aged patients with stage I (odds ratio, 5.04; 95% CI, 2.30-11.05) and stage II (odds ratio, 2.42; 95% CI, 1.58-3.72) disease were more likely to receive postoperative chemotherapy compared with older patients. Both groups were more likely to receive multiagent chemotherapy than were older patients (patients aged 18-49 years: odds ratio, 2.48; 95% CI, 1.42-4.32 and patients aged 50-64 years: odds ratio, 2.66; 95% CI, 1.70-4.18). Among patients who received surgery and postoperative systemic chemotherapy, no significant differences were observed in survival among age groups (the 95% CIs of hazard ratios included 1 for young and middle-aged patients compared with older patients for all tumor stages).In an equal-access health care system, we found potential overuse of chemotherapy among young and middle-aged adults with colon cancer. The addition of postoperative systemic chemotherapy did not result in matched survival improvement.
PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.
Authors: Ronald L. Paquette, Neil P. Shah, Charles L. Sawyers, Giovanni Martinelli, Nicoll John, Meenal Chalukya, Maurizio Rocchetti, Carina Fiocchi, Sylvia Comis, Laura Capolongo, Bernard Laffranchi
Journal: Blood (2007)
Generation-6 hydroxyl PAMAM dendrimers improve CNS penetration from intravenous administration in a large animal brain injury model
Authors: Fan Zhang, J. Trent Magruder, Yi-An Lin, Todd C. Crawford, Joshua C. Grimm, Christopher M. Sciortino, Mary Ann Wilson, Mary E. Blue, Sujatha Kannan, Michael V. Johnston, William A. Baumgartner, Rangaramanujam M. Kannan
Journal: Journal of Controlled Release (2017)
Is Hemoglobin A<sub>1c</sub> the Right Outcome for Studies of Diabetes?
Authors: Kasia J. Lipska, Harlan M. Krumholz
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AKIpredictor, an online prognostic calculator for acute kidney injury in adult critically ill patients: development, validation and comparison to serum neutrophil gelatinase-associated lipocalin
Authors: Marine Flechet, Fabian Güiza, Miet Schetz, Pieter Wouters, Ilse Vanhorebeek, Inge Derese, Jan Gunst, Isabel Spriet, Michaël Casaer, Greet Van den Berghe, Geert Meyfroidt
Journal: Intensive Care Medicine (2017)
HTLV-1 Adult T Cell Leukemia-Lymphoma Presenting with Refractory Hypercalcemia, Cranial Neuropathy and Diagnosis by Flow Cytometry and Cytogenetic Findings.
Authors: Seema Naik, Srinivas Kodali, Aref Agheli, Theresa Dumlao, Vijayant Singh, K. Plummer, William Steier, Madhumati Kalavar
Journal: Blood (2007)
Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function
Authors: Sharon Lim, Tzuen Yih Saw, Sandy Chang, Min Zhang, Matthew Robert Janes, David A Fruman, David A. Rizzieri, Soo-Yong Tan, Charles Chuah, S. Tiong Ong
Journal: Blood (2011)
Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys
Authors: Peter Ueda, Mark Woodward, Yuan Lu, Kaveh Hajifathalian, Rihab Al-Wotayan, Carlos A Aguilar-Salinas, Alireza Ahmadvand, Fereidoun Azizi, James Bentham, Renata Cifkova, Mariachiara Di Cesare, Louise Eriksen, Farshad Farzadfar, Trevor S Ferguson, Nayu Ikeda, Davood Khalili, Young-Ho Khang, Vera Lanska, Luz León-Muñoz, Dianna J Magliano, Paula Margozzini, Kelias P Msyamboza, Gerald Mutungi, Kyungwon Oh, Sophal Oum, Fernando Rodríguez-Artalejo, Rosalba Rojas-Martinez, Gonzalo Valdivia, Rainford Wilks, Jonathan E Shaw, Gretchen A Stevens, Janne S Tolstrup, Bin Zhou, Joshua A Salomon, Majid Ezzati, Goodarz Danaei
Journal: The Lancet Diabetes & Endocrinology (2017)
Protective Effects of No-Albumin and Albumin on Lung Injury Induced by Hypoxia/Reoxygenation in a Mouse Model of Sickle Cell Disease.
Authors: Lucia De Franceschi, Giorgio Malpeli, Anne Janin, Eva Muchitsch, Aldo Scarpa, Philippe Leboulch, Christhope Leboeuf, Yves Beuzard, Carlo Brugnara
Journal: Blood (2004)
Chronic Lymphocytic Leukemia Patients Exhibit Expanded Functional Granulocyte-like Myeloid Derived Suppressor Cells
Authors: Gerardo Ferrer, Rita Simone, Sonia Marsilio, Stefano Vergani, Andrea Nicola Mazzarello, Shih-Shih Chen, Xiao Jie Yan, Barbara Sherry, Jaqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2014)
Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.
Authors: Deborah Mukherji, Carmel Jo Pezaro, Diletta Bianchini, Andrea Zivi, Johann Sebastian De Bono
Journal: Journal of Clinical Oncology (2012)

17 Background: Abiraterone acetate (AA) has recently been approved for men with metastatic castration-resistant prostate cancer (CRPC) following docetaxel chemotherapy. AA inhibits CYP17, reducing androgen production and thereby impacting androgen receptor (AR) signalling. Recent evidence suggests taxanes also impact AR signalling, raising concerns about potential cross-resistance. We have previously shown that docetaxel has no antitumor activity in AA refractory patients. We have now evaluated the antitumor activity of AA post-docetaxel to determine the activity of AA in docetaxel refractory patients. Methods: Forty four men with CRPC treated with docetaxel (75 mg/m2 every 21 days) followed by post-chemotherapy AA at the Royal Marsden Hospital were identified. Radiological response by RECIST, PSA response by PSAWG2 criteria and symptomatic benefit were evaluated. Results: An average of 9 cycles of docetaxel were given (range 3-17); 7 patients discontinued chemotherapy due to progression of disease and 10 for toxicity. Of 40 patients with PSA data available, 26 (65%) had a PSA decline of at least 50%. At commencement of AA, median age was 68 years. Bone, nodal and visceral metastases were present in 38 (86%), 23 (52%) and 6 (14%) of the cohort respectively. An average of 5 months of treatment were delivered and 23 patients continue on AA. Of the 44, 7 (16%) patients had a 50% or greater PSA decline on AA. None of the 7 patients who were docetaxel refractory had a subsequent PSA, radiological or clinical response to AA. Of the 6 patients who received less than 5 cycles of docetaxel due to toxicity, 2 had subsequent PSA response on AA. There was no relationship between length of time on LHRH agonist and PSA response to AA. Conclusions: Our data suggest that patients who are refractory to docetaxel do not respond to AA. Overall, in conjunction with our other evidence that in AA-refractory patients docetaxel has no antitumor activity, these data provide further evidence for cross-resistance between these two agents.
Prolonged Strenuous Exercise Expands the Population of Developmentally Early Stem Cells in Bone Marrow (BM) and Mobilizes Them Into Peripheral Blood - Novel Evidence That Strongly Supports a Positive Effect of Physical Activity On Extension of Life Span At the Level of Stem Cells
Authors: Maciej Tarnowski, Katarzyna Piotrowska, Katarzyna Grymula, Malwina Suszynska, Agata Poniewierska, Mariusz Z Ratajczak
Journal: Blood (2012)
Determining true HER2 status in breast cancers with polysomy using alternative chromosome 17 reference genes: Implications for trastuzumab therapy.
Authors: A. M. Gown, C. C. Tse, L. C. Goldstein, P. L. Kandalaft, H. C. Hwang
Journal: Journal of Clinical Oncology (2010)

10549 Background: Detection of HER2 gene amplification by FISH is a key test to predict response of breast cancer to trastuzumab. The ratio of HER2 to CEP17 signals is often used to determine HER2 status, based on the assumption that centromeric probe to CEP17 indicates the chromosome 17 copy number. This study tests the hypothesis that increased copy numbers of CEP17 may not reflect the presence of polysomy and that the use of other genes on chromosome 17 might more accurately serve as reference genes to determine HER2 gene status. Methods: 122/5683 (2%) of HER2 FISH cases performed between October 2007 and December 2009 with CEP17 copy numbers 2.6 and above were selected for additional gene mapping studies using probes for other chromosome 17 genes, including SMS, RARA, and TP53. Revised HER2/chromosome-17-reference ratios utilizing these alternative loci were calculated. Results: 95/122 cases (78%) demonstrated at least one chromosome 17 gene locus with eusomic copy number. Using these new reference genes, 63 of 95 cases (66%) would have HER2 amplification status changed (negative to positive, equivocal to positive or negative to equivocal), with 46 cases (48%) now considered eligible for trastuzumab therapy. The cases were further divided into three groups based on level of HER2 signals (high [>6], intermediate [4-6], borderline/low [<4]) for analysis. The number of cases having HER2 status upgraded in these groups (high, intermediate and border/low) were 14/45 (31.1%), 43/50 (86%) and 4/27 (14.8%) respectively. Conclusions: Our results support recent findings of CGH studies suggesting that true polysomy 17 is rare in breast cancer, and that the CEP17 region is subject to chromosomal gains similar to other regions. Performing additional FISH using probes to the SMS, RARA and TP53 genes in order to obtain a HER2/chromosome-17-reference ratio is an effective way to determine the true HER2 amplification status in these
Analysis of FDG PET Diffuse Bone Marrow Uptake in Staging of Hodgkin’s Disease: A Reflect of Disease Infiltration or Just Inflammation?.
Authors: Pierre Y Salaun, Thomas Gastine, Loic Campion, Pierre Cambefort, Caroline Bodet-Milin, Anne Moreau, Steven Le Gouil, Jean-Luc Harousseau, Françoise Kraeber-Bodéré
Journal: Blood (2008)
Abstract B18: Role of the tumor suppressor gene DLC-2 in ERBB2 induced mouse mammary tumorigenesis and metastasis
Authors: Pratima Basak, Pratima Basak, Heather Leslie, Heather Leslie, Afshin Raouf, Afshin Raouf, Michael RA Mowat, Michael RA Mowat
Journal: Cancer Research (2016)

Abstract Introduction: Overexpression of dominant oncogenes and the loss of tumor suppressor genes are basic genetic events in acquisition of the malignant phenotype. The ERBB-2 proto-oncogene is overexpressed in 20% - 30% of human breast cancers. The tumor suppressor gene Deleted in liver cancer 2 (DLC-2, also known as STARD13) maps to chromosome 13q12.3 and is frequently downregulated by 72% in human breast cancer. It encodes a RhoGAP protein containing a START lipid binding domain. It is not known what role DLC-2 silencing plays in breast carcinogenesis. The purpose of our study is to assess the biological significance of inactivation of DLC-2 in ERBB2 induced mammary tumorigenesis mouse model. For this, we used MMTV-NIC mice, which carry an activated NEU oncogene (ERBB2) under control of the MMTV-LTR promoter that also co-expresses Cre recombinase. These mice were crossed to a conditional DLC-2 knockout mouse (floxed exon 3). Objectives: To determine if heterozygous or homozygous DLC-2 loss plays a role in mouse mammary tumor progression in MMTV-NIC mice. Results: Our preliminary results showed that heterozygous deletion of DLC-2 in the mammary epithelium of the MMTV-NIC mouse model resulted in increased tumor burden with accelerated tumor growth. Metastases to the lungs were quantified by scanning H&amp;E stained step sections (4X150uM). We observed a significant increase in the incidence of lung metastases in heterozygous DLC-2 exon3floxed/+ MMTV-NIC mice. The lung metastases showed a homogenous morphology and histopathologically similar phenotype to the MMTV-NIC strain. DLC-2 heterozygous tumor cells showed increased tumorosphere formation under low-attachment conditions with minimal growth factor supplementation. These tumor cells also showed increased expression of mesenchymal cell markers, as determined by quantitative real time RT-PCR, suggesting an Epithelial to Mesenchymal transition is occurring. Experiments with homozygous floxed DLC-2 mice are ongoing and will be presented. Conclusion: These results indicate that loss of one allele of DLC-2 is sufficient to accelerate NEU oncogene induced tumorigenesis. Citation Format: Pratima Basak, Pratima Basak, Heather Leslie, Heather Leslie, Afshin Raouf, Afshin Raouf, Michael RA Mowat, Michael RA Mowat. Role of the tumor suppressor gene DLC-2 in ERBB2 induced mouse mammary tumorigenesis and metastasis. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B18.
Characterization of an Anti-Factor VIII Monoclonal Antibody with A1 and A3 Epitopes Which Increases Factor VIII Activity.
Authors: Masahiro Takeyama, Keiji Nogami, Tetsuhiro Soeda, Tsukasa Suzuki, Kunihiro Hattori, Kohei Tatsumi, Yuri Fujita, Ichiro Tanaka, Akira Yoshioka, Midori Shima
Journal: Blood (2006)
High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)
Authors: Roelof Willemze, Stefan Suciu, Franco Mandelli, Boris Labar, Jean-Pierre Marie, Martin Mistrik, Vincenzo Liso, Francesco Fabbiano, Francesco Nobile, Marco Sborgia, Bruno Rotoli, Dominik L.D. Selleslag, Francois Lefrere, Antonio Peta, Massimo F Martelli, Giuseppe Leone, Nicola Cantore, Meral Beksac, Zwi Berneman, Xavier Thomas, Michele Mario Greco, Dominique Bron, Georges Fillet, Jose E. Guimaraes, Petra Muus, Paola Fazi, Liliana Baila, Marco Vignetti, Sergio Amadori, Giovanna Meloni
Journal: Blood (2008)
Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL
Authors: Luke Jones, Jennifer Richmond, Kathryn Evans, Hernan Carol, Duohui Jing, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research (2017)

Purpose: Robust preclinical models of pediatric acute lymphoblastic leukemia (ALL) are essential in prioritizing promising therapies for clinical assessment in high-risk patients. Patient-derived xenograft (PDX) models of ALL provide a clinically relevant platform for assessing novel drugs, with efficacy generally assessed by enumerating circulating human lymphoblasts in mouse peripheral blood (PB) as an indicator of disease burden. While allowing indirect measurement of disease burden in real time, this technique cannot assess treatment effects on internal reservoirs of disease. We explore benefits of bioluminescence imaging (BLI) to evaluate drug responses in ALL PDXs, compared with PB monitoring. BLI-based thresholds of drug response are also explored.Experimental Design: ALL PDXs were lentivirally transduced to stably express luciferase and green fluorescent protein. In vivo PDX responses to an induction-type regimen of vincristine, dexamethasone, and L-asparaginase were assessed by BLI and PB. Residual disease at day 28 after treatment initiation was assessed by flow cytometric analysis of major organs. BLI and PB were subsequently used to evaluate efficacy of the Bcl-2 inhibitor venetoclax.Results: BLI considerably accelerated and enhanced detection of leukemia burden compared with PB and identified sites of residual disease during treatment in a quantitative manner, highlighting limitations in current PB-based scoring criteria. Using BLI alongside enumeration of human lymphoblasts in PB and bone marrow, we were able to redefine response criteria analogous to the clinical setting.Conclusions: BLI substantially improves the stringency of preclinical drug testing in pediatric ALL PDXs, which will likely be important in prioritizing effective agents for clinical assessment. Clin Cancer Res; 23(14); 3744-55. ©2017 AACR.
Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)
Authors: Pieter Sonneveld, Meral Beksac, Bronno van der Holt, Meletios A. Dimopoulos, Angelo Michele Carella, Heinz Ludwig, Christoph Driessen, Ruth Wester, Roman Hajek, Sandra Croockewit, Rossella Troia, Francesca Gay, Anna Maria Cafro, Luca De Rosa, G Fioritoni, Ulf-Henrik Mellqvist, Hans Erik Johnsen, Sonja Zweegman, Ka Lung Wu, Joana Parreira, Fredrik H. Schjesvold, James D'Rozario, Antonio Palumbo, Michele Cavo
Journal: Blood (2016)
Proportion and Cost of Unplanned 30-Day Readmissions After Sepsis Compared With Other Medical Conditions
Authors: Florian B. Mayr, Victor B. Talisa, Vikram Balakumar, Chung-Chou H. Chang, Michael Fine, Sachin Yende
Journal: JAMA (2017)

This study uses data from a US readmissions database to assess whether sepsis hospitalizations account for a higher proportion of unplanned 30-day readmissions than hospitalizations for acute myocardial infarction, heart failure, chronic obstructive pulmonary disease, and pneumonia.
Synergism Between HOXA9 and Mutant JAK3 (M511I) Leads to Rapid Leukemia Development within an in Vivo Murine Bone Marrow Transplant Model
Authors: Charles E de Bock, Sandrine Degryse, Sofie Demeyer, Bram Sweron, Olga Gielen, Nicole Mentens, Ellen Geerdens, Jan Cools
Journal: Blood (2014)
Anti-Leukemic Activity of a Novel Pegylated Recombinant Erwinia Chrysanthemi-Derived L-Asparaginase On Lymphoid Cell Lines and Leukemia-Bearing Mouse Models.
Authors: Wei-Wen Chien, Céline Lebeux, Nicolas Rachinel, Soraya Allas, Pierre Sahakian, Michel Julien, Claire Lacroix, Thierry Abribat, Gilles Salles
Journal: Blood (2012)
Correlation of Hepatocyte Iron Score and Liver Iron Ratio with Alanine Aminotransferase in Patients with Beta Thalassemia Receiving Iron Chelation Therapy for at Least 3 Years
Authors: M Domenica Cappellini, Mohamed Bejaoui, Silverio Perrotta, Leyla Agaoglu, Antonis Kattamis, Jackie Han, Ali El-Ali, John B Porter
Journal: Blood (2015)
FRMD4A / RET : A Novel RET Oncogenic Fusion Variant in Non–Small Cell Lung Carcinoma
Authors: Vamsidhar Velcheti, Rajat Thawani, Monica Khunger, Sanjay Mukhopadhyay, Deborah J. Chute, Alexa B. Schrock, Siraj M. Ali
Journal: Journal of Thoracic Oncology (2017)
GENO-08NEXT GENERATION SEQUENCING REVEALS DISTINCT PROGNOSTIC CLASSES AMONG GRADE II/III GLIOMAS
Authors: Erica Bell, Oliver Oehlke, Jessica Fleming, Arup Chakraborty, Joe McElroy, Cynthia Timmers, Andrea Salavaggione, Ori Staszewski, Marco Prinz, Anca Grosu, Arnab Chakravarti
Journal: Neuro-Oncology (2015)

BACKGROUND: WHO grade II and III gliomas are heterogeneous both genotypically and phenotypically.Genomic characterization and prognostic classification of grade II and III gliomas has only recently begun to be elucidated.Therefore, we retrospectively analyzed an institutional cohort of grade II/III gliomas (n ¼ 62).METHODS: A custom Ion Torrent next generation sequencing panel was used to sequence IDH1, IDH2, CIC, FUBP1, and ATRX.TERT promoter mutations were analyzed by Sanger sequencing.1p/